Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aquestive Therapeutics Inc's Business Segments
Aquestive Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 14
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 14 | 100% |
Revenue Share by Region - Q1 FY2026
- Non-US8.3%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 1 | 8.3% |
Revenue by Product & Service Category - Q1 FY2026
- Manufacture and supply revenue60.9%
- License and royalty revenue37.3%
- Co-development and research fees1.8%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Manufacture and supply revenue | $ 9 | 60.9% |
| License and royalty revenue | $ 5 | 37.3% |
| Co-development and research fees | $ 0 | 1.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue by Product & Service Category -
- Royalty2.1%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 1 | 2.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Aquestive Therapeutics Inc
Aquestive Therapeutics Inc. is a pharmaceutical company that specializes in developing and commercializing innovative products to address unmet medical needs. The company is headquartered in New Jersey, United States, and was founded in 2004. Aquestive Therapeutics operates as a publicly traded company under the ticker symbol AQST on the NASDAQ stock exchange.
The company focuses on developing orally administered therapeutics and complex molecules in different therapeutic areas, such as central nervous system (CNS) disorders, otolaryngology, and critical care. The goal of Aquestive Therapeutics is to enhance medication delivery and improve patient outcomes through its proprietary drug delivery technologies.
One of the flagship technologies developed by Aquestive Therapeutics is PharmFilm, a thin, orally dissolving film that delivers medication directly into the bloodstream through the buccal mucosa. PharmFilm enables rapid absorption and bypasses the gastrointestinal tract, which can have significant benefits in certain patient populations, such as those with dysphagia or who have difficulty swallowing medication. This technology has the potential to improve medication adherence, convenience, and efficacy.
Aquestive Therapeutics has a diverse portfolio of product candidates in various stages of development. Some of the key therapeutic areas the company focuses on include the treatment of epilepsy, attention-deficit hyperactivity disorder (ADHD), opioid withdrawal, and vasomotor symptoms associated with menopause.
Aquestive Therapeutics' lead product candidate is Libervant, an oral soluble film formulation of diazepam for the management of seizure clusters or acute repetitive seizures. The company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Libervant in September 2020, and it has been granted Priority Review designation by the FDA, indicating the potential for an expedited review process.
In addition to Libervant, Aquestive Therapeutics has several other product candidates in its pipeline. Riluzole Oral Soluble Film (OSF) is another noteworthy candidate being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disorder. The company is also developing a novel pharmacokinetic-based oral film formulation of risperidone, a medication used in the treatment of schizophrenia and bipolar disorder.
Apart from its own product candidates, Aquestive Therapeutics has entered into partnerships and collaborations with pharmaceutical and biotech companies to leverage its drug delivery technologies. The company has collaborations with global healthcare companies such as Sunovion Pharmaceuticals, Teva Pharmaceutical Industries, and Strativa Pharmaceuticals.
In terms of intellectual property, Aquestive Therapeutics holds a sizable patent portfolio to protect its proprietary technologies and product candidates. The company has filed numerous patent applications related to its PharmFilm technology and other drug delivery platforms.
Overall, Aquestive Therapeutics Inc. is a pharmaceutical company specializing in innovative drug delivery technologies to improve medication delivery and patient outcomes. With a focus on CNS disorders and other therapeutic areas, the company's product candidates and collaborations aim to make a significant impact in the pharmaceutical industry.
The company focuses on developing orally administered therapeutics and complex molecules in different therapeutic areas, such as central nervous system (CNS) disorders, otolaryngology, and critical care. The goal of Aquestive Therapeutics is to enhance medication delivery and improve patient outcomes through its proprietary drug delivery technologies.
One of the flagship technologies developed by Aquestive Therapeutics is PharmFilm, a thin, orally dissolving film that delivers medication directly into the bloodstream through the buccal mucosa. PharmFilm enables rapid absorption and bypasses the gastrointestinal tract, which can have significant benefits in certain patient populations, such as those with dysphagia or who have difficulty swallowing medication. This technology has the potential to improve medication adherence, convenience, and efficacy.
Aquestive Therapeutics has a diverse portfolio of product candidates in various stages of development. Some of the key therapeutic areas the company focuses on include the treatment of epilepsy, attention-deficit hyperactivity disorder (ADHD), opioid withdrawal, and vasomotor symptoms associated with menopause.
Aquestive Therapeutics' lead product candidate is Libervant, an oral soluble film formulation of diazepam for the management of seizure clusters or acute repetitive seizures. The company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Libervant in September 2020, and it has been granted Priority Review designation by the FDA, indicating the potential for an expedited review process.
In addition to Libervant, Aquestive Therapeutics has several other product candidates in its pipeline. Riluzole Oral Soluble Film (OSF) is another noteworthy candidate being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disorder. The company is also developing a novel pharmacokinetic-based oral film formulation of risperidone, a medication used in the treatment of schizophrenia and bipolar disorder.
Apart from its own product candidates, Aquestive Therapeutics has entered into partnerships and collaborations with pharmaceutical and biotech companies to leverage its drug delivery technologies. The company has collaborations with global healthcare companies such as Sunovion Pharmaceuticals, Teva Pharmaceutical Industries, and Strativa Pharmaceuticals.
In terms of intellectual property, Aquestive Therapeutics holds a sizable patent portfolio to protect its proprietary technologies and product candidates. The company has filed numerous patent applications related to its PharmFilm technology and other drug delivery platforms.
Overall, Aquestive Therapeutics Inc. is a pharmaceutical company specializing in innovative drug delivery technologies to improve medication delivery and patient outcomes. With a focus on CNS disorders and other therapeutic areas, the company's product candidates and collaborations aim to make a significant impact in the pharmaceutical industry.
Aquestive Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative therapeutic products and drug delivery technologies. The company focuses on addressing unmet medical needs for patients with complex conditions, particularly in the areas of central nervous system disorders and other chronic diseases.
Segments
1. Pediatric and Adult Therapeutics:
- Aquestive Therapeutics develops medications aimed at both pediatric and adult populations, addressing issues such as adherence to treatment protocols and ease of administration.
2. Specialty Pharmaceuticals:
- The company operates in the specialty pharmaceutical sector, which typically involves targeted therapies for specific patient populations. These may include products that cater to rare diseases or niche market conditions.
3. Drug Delivery Technologies:
- A substantial segment of Aquestive’s business involves its proprietary drug delivery platforms. This includes technologies designed to facilitate the administration of drugs via innovative routes, such as sublingual delivery.
Products
1. Sympazan (clobazam):
- A key product, Sympazan, is an oral film formulation of clobazam, an anti-epileptic medication used to treat seizures associated with Lennox-Gastaut syndrome. This delivery format aims to enhance patient compliance by providing a convenient and palatable option.
2. Kynmobi (apomorphine):
- Kynmobi is an innovative sublingual strip formulation of apomorphine designed for the acute, intermittent treatment of offepisodes in patients with Parkinsons disease. Its formulation addresses difficulties some patients face with traditional delivery methods.
3. Libervant (diazepam):
- Libervant is an intranasal formulation of diazepam for the treatment of seizures. It provides an alternative for patients who may have difficulty with more conventional dosage forms, facilitating easier and quicker administration during seizure episodes.
4. Other Development Candidates:
- In addition to its approved products, Aquestive Therapeutics has several other drug delivery candidates in various stages of development. These candidates aim to optimize pharmacokinetics, improve patient adherence, and deliver medications more effectively for various medical conditions.
Services
1. Regulatory Support:
- The company offers services related to navigating regulatory pathways for drug approval, ensuring that their products meet the necessary health authority standards.
2. Clinical Development:
- A dedicated team supports clinical trial design and execution, helping to bring new therapies and formulations to market efficiently.
3. Partnership and Licensing Opportunities:
- Aquestive is open to partnerships and collaborations with other pharmaceutical companies, researchers, and institutions to co-develop therapies and leverage its drug delivery technologies.
4. Patient Support Programs:
- The company is committed to ensuring access to its therapies through patient support programs that may include education, adherence support, and assistance with insurance coverage.
5. Formulation Development Services:
- Aquestive offers its expertise in formulation development to other pharmaceutical companies, specifically focusing on improving drug delivery systems and enhancing bioavailability of poorly soluble compounds.
Conclusion
In summary, Aquestive Therapeutics Inc. operates across multiple segments, developing therapeutics and novel drug delivery technologies aimed at improving patient outcomes. Its focus on patient-centric delivery solutions, particularly in the pediatric and specialty pharmaceutical arenas, highlights its commitment to addressing complex medical needs effectively. The companys comprehensive suite of products and services enriches its position in the biopharmaceutical landscape, setting the stage for future growth and innovation in the therapeutic realm.
Segments
1. Pediatric and Adult Therapeutics:
- Aquestive Therapeutics develops medications aimed at both pediatric and adult populations, addressing issues such as adherence to treatment protocols and ease of administration.
2. Specialty Pharmaceuticals:
- The company operates in the specialty pharmaceutical sector, which typically involves targeted therapies for specific patient populations. These may include products that cater to rare diseases or niche market conditions.
3. Drug Delivery Technologies:
- A substantial segment of Aquestive’s business involves its proprietary drug delivery platforms. This includes technologies designed to facilitate the administration of drugs via innovative routes, such as sublingual delivery.
Products
1. Sympazan (clobazam):
- A key product, Sympazan, is an oral film formulation of clobazam, an anti-epileptic medication used to treat seizures associated with Lennox-Gastaut syndrome. This delivery format aims to enhance patient compliance by providing a convenient and palatable option.
2. Kynmobi (apomorphine):
- Kynmobi is an innovative sublingual strip formulation of apomorphine designed for the acute, intermittent treatment of offepisodes in patients with Parkinsons disease. Its formulation addresses difficulties some patients face with traditional delivery methods.
3. Libervant (diazepam):
- Libervant is an intranasal formulation of diazepam for the treatment of seizures. It provides an alternative for patients who may have difficulty with more conventional dosage forms, facilitating easier and quicker administration during seizure episodes.
4. Other Development Candidates:
- In addition to its approved products, Aquestive Therapeutics has several other drug delivery candidates in various stages of development. These candidates aim to optimize pharmacokinetics, improve patient adherence, and deliver medications more effectively for various medical conditions.
Services
1. Regulatory Support:
- The company offers services related to navigating regulatory pathways for drug approval, ensuring that their products meet the necessary health authority standards.
2. Clinical Development:
- A dedicated team supports clinical trial design and execution, helping to bring new therapies and formulations to market efficiently.
3. Partnership and Licensing Opportunities:
- Aquestive is open to partnerships and collaborations with other pharmaceutical companies, researchers, and institutions to co-develop therapies and leverage its drug delivery technologies.
4. Patient Support Programs:
- The company is committed to ensuring access to its therapies through patient support programs that may include education, adherence support, and assistance with insurance coverage.
5. Formulation Development Services:
- Aquestive offers its expertise in formulation development to other pharmaceutical companies, specifically focusing on improving drug delivery systems and enhancing bioavailability of poorly soluble compounds.
Conclusion
In summary, Aquestive Therapeutics Inc. operates across multiple segments, developing therapeutics and novel drug delivery technologies aimed at improving patient outcomes. Its focus on patient-centric delivery solutions, particularly in the pediatric and specialty pharmaceutical arenas, highlights its commitment to addressing complex medical needs effectively. The companys comprehensive suite of products and services enriches its position in the biopharmaceutical landscape, setting the stage for future growth and innovation in the therapeutic realm.